Incurin® — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Incurin®

Active ingredient

estriol

Application type

NADA

Sponsor

Intervet, Inc.

Applications on record

1

First published

September 21, 2020

Adverse event reports

Source: openFDA VeDDRA

680

Reports mentioning this ingredient

August 3, 2011 – March 20, 2026

140

Classified serious

per reporter assessment

284

Lack of expected efficacy

resistance signal

6

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “ESTRIOL”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Lack of efficacy - NOS	227
Vaginal swelling	82
Anorexia	32
Vomiting	29
Death by euthanasia	27
Polydipsia	18
Vulvitis	17
Depression	16
Anaemia NOS	14
Increased sexual interest	14
Diarrhoea	13
Thrombocytopenia	13
Urinary tract infection	13
Aggression	12
Polyuria	11
Alopecia NOS	10
Vaginal haemorrhage	9
Excessive licking and/or grooming	9
Weight loss	9
Elevated alanine aminotransferase (ALT)	9

Species affected

Source: openFDA VeDDRA

Dog 679 Rat 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient